FMC Science, LLC | Lampasas, NY

Research site

(Unclaimed)

Location

207 W Avenue E, Lampasas, New York, United States of America

Site insights

Top conditions

Top treatments

Elagolix

Rimegepant

Testosterone

K-877

Estradiol

Triglyceride

Sugar

Insulin icodec

Norethindrone Acetate

RPL554

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 45 total trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling

Type 2 Diabetes

Drug: Semaglutide

Drug: Cagrilintide

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Active, not recruiting

Type 2 Diabetes

Drug: IcoSema

Drug: Insulin glargine

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Placebo

Drug: Olezarsen

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The seco...

Active, not recruiting

Contraception

Change in Bone Mineral Density

Drug: Drospirenone

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diab...

Active, not recruiting

Diabetic Cardiomyopathies

Drug: AT-001

Drug: Placebo

Locations recently updated

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relati...

Enrolling

Endometriosis

Drug: Elagolix

Drug: Placebo

Locations recently updated

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant